Sign in →

Test ID LBOR0149 DPYD Genotyping

Important Note

This test is rarely covered by insurance.  A Patient Acknowledgement Form for Pharmacogenomics Services is required to accompany the specimen for all Medicare and non-Medicare patients.  In addition, for Medicare patients, and ABN Form should also be submitted.  In the absence of the appropriate signed form(s), the ordering provider/facility will be billed.

For patients with Blue Cross Blue Shield of North Dakota coverage, a separate completed and signed Advance Member Notice is required to accompany the specimen.

Specimen Type/Requirements

Lavender top (EDTA) -  Whole Blood (preferred)

Sterile container - Extracted DNA

 

All specimens should be sent in the original container and should not be aliquoted to another tube. In addition, the specimen submitted should ONLY be used for this testing and should not be shared with any other testing that would also utilize this specimen type.

 

This testing requires that a Patient Acknowledgement Form for Pharmacogenomics Services must be filled out for all Medicare and non-Medicare patients  and submitted with the sample for testing to be performed. In addition, Medicare patients require an  ABN Form to also be submitted with the specimen.

 

For patients with Blue Cross Blue Shield of North Dakota coverage, a separate completed and signed Advance Member Notice is required to be submitted with the specimen.

 

Test is not affected by hemolysis or lipemia. 

Specimen Volume

 

Preferred Volume   2.0 - 4.0 mL  
Minimum Volume   1.0 mL  

 

Stability/Transport

 

Room Temperature   72 hours    
Refrigerated   7 days   preferred for transport  
Frozen   7 days    

 

 

Performed Test Frequency

Monday through Friday

Methodology

Allele-specific PCR

Performing Lab

Sanford Molecular

Analytic Time

5 – 7 days

CPT

81232

Additional Information

See Dihydropyrimidine Dehydrogenase (DPYD) Genotyping for additional information. 

AKA

Fluoropyrimidine

5-Fluorouracil

Capecitabine

 

Useful For

  • Estimate genetic risk of dose-related toxicity with 5-fluorouracil (5-FU) and capecitabine.
  • Identify genotypes shown to have a drug-gene variant relationship.